Ksilink is a deeptech exploiting a pipeline of patient-based drug discovery programs

  1. Home
  2.  » Our Story

Our story

What we do

Leveraging our network of academia, industry, patients’ organizations, and clusters, we are bridging academic and industrial forces to address diseases where no other therapeutic approaches have proven effective or ever existed.

Our business model

We conduct a pipeline of patient-based drug discovery programs in muscular and neurological disorders. We develop them as collaborative proprietary programs up to novel therapeutic candidates to be further developed by the pharmaceutical industry.

Our differentiating features

  • We develop and exploit complex patient-based disease models for drug discovery thanks to AI. ​
  • We align expertise in an end-to end approach to access best experts, derisk innovation, and accelerate research.​

Our why

  • Discovering new drugs solving today’s unmet medical needs.
  • Advancing science by making outstanding expertise available and reliable for the pharmaceutical industry.
  • Achieving great outcomes faster by building precision networks in an integrated end-to-end approach.

LAUNCH

Derisking innovation with public funding

The project is launched is set up thanks to strong impulse from Inserm and Sanofi, and 16m€ funding from French Programme d’Investissement d’Avenir (PIA).

InsermSanofiInvestir l'avenir

2015

ACCELERATION

Moving Ksilink to the next step

With proof-of-concept now established, it is decided to accelerate and substitute own staff and equipment to in-kind contributions from the members. Ksilink recruits own staff and invest into a tailored fully-automated sterile screening platform.

Ksilink acceleration

2019

EXPLOITATION

Incorporation of Ksilink SAS

The technology platform and the team are transferred to a spin-off in the form of a limited company (SAS) to exploit generated results and drive pipeline to valuable endpoints for the industry.

Ksilink - Patient-based drug discovery

2022

TODAY
ADVANCING PIPELINE TO THE NEXT VALUE INFLECTION POINTS